(+)-WAY-161503 | 276694-95-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (+)-WAY-161503
• 英文别名: (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one；(R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-one；(4aR)-8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one
• CAS: 276694-95-2
• 化学式: C₁₁H₁₁Cl₂N₃O
• 分子量: 272.134
• InChiKey: PHGWDAICBXUJDU-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+)-WAY-161503 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 生成 (R)-8,9-dichloro-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline
  参考文献：
  名称：

  Synthesis and 5-Hydroxytryptamine (5-HT) activity of 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxalines

  摘要：

  A series of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]-quinoxalines was shown to exhibit 5-HT2C agonist binding and Functional activity. Compound 21R inhibited food intake over 2 h in fasted, male Sprague-Dawley rats with ED50 values of 2 mg/kg (ip) and 10 mg/kg (po). (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00400-5
• 作为产物：
  描述：

  (R)-4-carbobenzyloxy-1-(4,5-dichloro-2-nitrophenyl)-piperazine-2-carboxylic acid 在 铁粉 乙酸乙酯 、 盐酸 、 水 、 Brine 、 magnesium sulfate 、 ethyl acetate n-hexane 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 以to afford 5.44 g (76.1%) of title compound as a white solid, mp 136-138° C.的产率得到(+)-WAY-161503
  参考文献：
  名称：

  2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives

  摘要：

  该发明提供了I式化合物，其中1R为氢或1-6碳原子的烷基；R′为氢，1-6碳原子的烷基，2-7碳原子的酰基或芳基；R1、R2、R3和R4各自独立地为氢、1-6碳原子的烷基、1-6碳原子的烷氧基、卤素、三氟甲基、—CN、1-6碳原子的烷基磺酰胺、1-6碳原子的烷基酰胺、氨基、1-6碳原子的烷基氨基、1-6碳原子的二烷基氨基、每个烷基部分的三氟甲氧基、2-7碳原子的酰基或芳基；X为CR5R6或羰基基团；R5和R6各自独立地为氢或1-6碳原子的烷基；或其药学上可接受的盐，但至少R1、R2、R3或R4中的一个不为氢；这些化合物是5HT2C受体激动剂，用于治疗涉及中枢神经系统的疾病，如强迫症、抑郁症、焦虑症、精神分裂症、偏头痛、睡眠障碍、进食障碍、肥胖症、2型糖尿病和癫痫。

  公开号：

  US20030060468A1

文献信息

• 2,3,4,4a-tetrahydro-1H-pyrazino-[1,2a] quinoxalin-5- (6H) one derivatives
  申请人：American Home Products Corporation

  公开号：US20010051622A1

  公开（公告）日：2001-12-13

  This invention provides compounds of formula I, 1 wherein R is hydrogen or alkyl of 1-6 carbon atoms; R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R 1 , R 2 , R 3 , and R 4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; X is CR 5 R 6 or a carbonyl group; R 5 and R 6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R 1 , R 2 , R 3 , or R 4 are not hydrogen; which are 5HT 2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, type II diabetes, and epilepsy.

  该发明提供了以下化合物，其中：R为氢或1-6个碳原子的烷基；R′为氢、1-6个碳原子的烷基、2-7个碳原子的酰基或芳酰基；R1、R2、R3和R4分别独立地为氢、1-6个碳原子的烷基、1-6个碳原子的烷氧基、卤素、三氟甲基、氰基、1-6个碳原子的烷基磺酰胺、1-6个碳原子的烷基酰胺、氨基、1-6个碳原子的烷基氨基、每个烷基基团的1-6个碳原子的二烷基氨基、1-6个碳原子的三氟甲氧基、2-7个碳原子的酰基或芳酰基；X为CR5R6或羰基；R5和R6分别独立地为氢或1-6个碳原子的烷基；或其药用盐，但至少其中一个R1、R2、R3或R4不为氢；这些化合物为5HT2C受体激动剂，适用于治疗涉及中枢神经系统的疾病，如强迫症、抑郁症、焦虑症、精神分裂症、偏头痛、睡眠障碍、进食障碍、肥胖症、2型糖尿病和癫痫等。
• 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
  申请人：Wyeth

  公开号：US06476032B2

  公开（公告）日：2002-11-05

  This invention provides compounds of formula I, wherein R is hydrogen or alkyl of 1-6 carbon atoms; R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; X is CR5R6 or a carbonyl group; R5 and R6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R1, R2, R3, or R4 are not hydrogen; which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, type II diabetes, and epilepsy.

  这项发明提供了以下式I的化合物，其中R为氢或1-6个碳原子的烷基；R′为氢，1-6个碳原子的烷基，2-7个碳原子的酰基，或芳基；R1、R2、R3和R4分别独立地为氢，1-6个碳原子的烷基，1-6个碳原子的烷氧基，卤素，三氟甲基，—CN，1-6个碳原子的烷基磺酰胺，1-6个碳原子的烷酰胺，氨基，1-6个碳原子的烷基氨基，每个烷基部分的1-6个碳原子的二烷基氨基，1-6个碳原子的三氟甲氧基，2-7个碳原子的酰基，或芳基；X为CR5R6或羰基；R5和R6分别独立地为氢或1-6个碳原子的烷基；或其药学上可接受的盐，但要求R1、R2、R3或R4中至少有一个不是氢；这些化合物是5HT2C受体激动剂，用于治疗涉及中枢神经系统的疾病，如强迫症、抑郁症、焦虑症、精神分裂症、偏头痛、睡眠障碍、进食障碍、肥胖症、2型糖尿病和癫痫。
• 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives
  申请人：Wyeth

  公开号：US20040116437A1

  公开（公告）日：2004-06-17

  This invention provides compounds of formula I, 1 wherein R is hydrogen or alkyl of 1-6 carbon atoms; R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R 1 , R 2 , R 3 , and R 4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, or trifluoroalkoxy of 1-6 carbon atoms; X is CR 5 R 6 or a carbonyl group; R 5 and R 6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least two of R 1 , R 2 , R 3 , or R 4 are not hydrogen; which are 5HT 2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, type II diabetes, and epilepsy.

  该发明提供了式I，其中R为氢或1-6个碳原子的烷基；R′为氢，1-6个碳原子的烷基，2-7个碳原子的酰基或芳基；R1、R2、R3和R4分别独立地为氢，1-6个碳原子的烷基，1-6个碳原子的烷氧基，卤素，三氟甲基或1-6个碳原子的三氟甲氧基；X为CR5R6或羰基基团；R5和R6分别独立地为氢或1-6个碳原子的烷基；或其药学上可接受的盐，但至少有两个R1、R2、R3或R4不是氢。这些化合物是5HT2C受体激动剂，可用于治疗涉及中枢神经系统的疾病，如强迫症、抑郁症、焦虑症、精神分裂症、偏头痛、睡眠障碍、进食障碍、肥胖症、2型糖尿病和癫痫。
• 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
  申请人：Wyeth

  公开号：US20030060468A1

  公开（公告）日：2003-03-27

  This invention provides compounds of formula I, 1 R is hydrogen or alkyl of 1-6 carbon atoms; R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R 1 , R 2 , R 3 , and R 4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; X is CR 5 R 6 or a carbonyl group; R 5 and R 6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R 1 , R 2 , R 3 , or R 4 are not hydrogen; which are 5HT 2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, type II diabetes, and epilepsy.

  该发明提供了I式化合物，其中1R为氢或1-6碳原子的烷基；R′为氢，1-6碳原子的烷基，2-7碳原子的酰基或芳基；R1、R2、R3和R4各自独立地为氢、1-6碳原子的烷基、1-6碳原子的烷氧基、卤素、三氟甲基、—CN、1-6碳原子的烷基磺酰胺、1-6碳原子的烷基酰胺、氨基、1-6碳原子的烷基氨基、1-6碳原子的二烷基氨基、每个烷基部分的三氟甲氧基、2-7碳原子的酰基或芳基；X为CR5R6或羰基基团；R5和R6各自独立地为氢或1-6碳原子的烷基；或其药学上可接受的盐，但至少R1、R2、R3或R4中的一个不为氢；这些化合物是5HT2C受体激动剂，用于治疗涉及中枢神经系统的疾病，如强迫症、抑郁症、焦虑症、精神分裂症、偏头痛、睡眠障碍、进食障碍、肥胖症、2型糖尿病和癫痫。
• Treatment of incontinence with 5htc2 agonists
  申请人：Pfizer Inc.

  公开号：EP2277513A2

  公开（公告）日：2011-01-26

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of stress urinary incontinence. The present invention also relates to a method of treatment of stress urinary incontinence, to assays to screen for compounds useful in the treatment of stress urinary incontinence, and to methods of preparing compositions for the treatment of stress urinary incontinence.

  本发明涉及使用5-HT2C受体激动剂治疗压力性尿失禁。本发明还涉及一种治疗压力性尿失禁的方法，涉及筛选用于治疗压力性尿失禁的化合物的检测方法，以及涉及制备治疗压力性尿失禁的组合物的方法。